New generations of dihydropyridines for treatment of hypertension

Since the calcium channel blocker (CCB) has become one of the most prescribed agents for antihypertensive monotherapy in the world, this brief review will focus on the recent research and development of the dihydropyridine (DHP) CCB, addressing pharmacological mechanisms for the clinical efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Angela L, Iadecola, Costantino, Wang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329735/
https://www.ncbi.nlm.nih.gov/pubmed/28270844
http://dx.doi.org/10.11909/j.issn.1671-5411.2017.01.006
_version_ 1782511114502799360
author Wang, Angela L
Iadecola, Costantino
Wang, Gang
author_facet Wang, Angela L
Iadecola, Costantino
Wang, Gang
author_sort Wang, Angela L
collection PubMed
description Since the calcium channel blocker (CCB) has become one of the most prescribed agents for antihypertensive monotherapy in the world, this brief review will focus on the recent research and development of the dihydropyridine (DHP) CCB, addressing pharmacological mechanisms for the clinical efficacy of the third and fourth generations of the DHP CCBs, especially on their possible central mechanisms underlying lowering blood pressure.
format Online
Article
Text
id pubmed-5329735
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Science Press
record_format MEDLINE/PubMed
spelling pubmed-53297352017-03-07 New generations of dihydropyridines for treatment of hypertension Wang, Angela L Iadecola, Costantino Wang, Gang J Geriatr Cardiol Review Since the calcium channel blocker (CCB) has become one of the most prescribed agents for antihypertensive monotherapy in the world, this brief review will focus on the recent research and development of the dihydropyridine (DHP) CCB, addressing pharmacological mechanisms for the clinical efficacy of the third and fourth generations of the DHP CCBs, especially on their possible central mechanisms underlying lowering blood pressure. Science Press 2017-01 /pmc/articles/PMC5329735/ /pubmed/28270844 http://dx.doi.org/10.11909/j.issn.1671-5411.2017.01.006 Text en Institute of Geriatric Cardiology http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission.
spellingShingle Review
Wang, Angela L
Iadecola, Costantino
Wang, Gang
New generations of dihydropyridines for treatment of hypertension
title New generations of dihydropyridines for treatment of hypertension
title_full New generations of dihydropyridines for treatment of hypertension
title_fullStr New generations of dihydropyridines for treatment of hypertension
title_full_unstemmed New generations of dihydropyridines for treatment of hypertension
title_short New generations of dihydropyridines for treatment of hypertension
title_sort new generations of dihydropyridines for treatment of hypertension
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329735/
https://www.ncbi.nlm.nih.gov/pubmed/28270844
http://dx.doi.org/10.11909/j.issn.1671-5411.2017.01.006
work_keys_str_mv AT wangangelal newgenerationsofdihydropyridinesfortreatmentofhypertension
AT iadecolacostantino newgenerationsofdihydropyridinesfortreatmentofhypertension
AT wanggang newgenerationsofdihydropyridinesfortreatmentofhypertension

Ejemplares similares